Atezolizumab plus pirfenidone for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 1/2 trial tests whether combining atezolizumab and pirfenidone can help people with non-small cell lung cancer (NSCLC) after prior treatment. It is aimed at patients whose cancer has certain genetic markers ruled out and who can safely take study medicines and follow frequent visits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and can sign consent (or your legal representative can).
- You have confirmed non-small cell lung cancer that is advanced (stage IV) or coming back, or unresectable stage III that can’t be removed by surgery.
- Your cancer tests show no “actionable” gene changes (like EGFR, ALK, or ROS-1).
- You have at least one measurable tumor spot that doctors can track on scans.
- You must be able to take pills by mouth, attend scheduled visits, and complete required blood/organ tests.
- Your lung/heart health must be safe for this study (including good enough organ function and heart tests).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a two-drug treatment (cabozantinib plus atezolizumab) for people with advanced or metastatic non-small cell lung cancer (NSCLC). It may help control the cancer and shrink tumors, especially for patients whose tumor tests show low PD-L1 and who fit the trial’s prior-treatment rules.
This trial tests a drug called atezolizumab, an immunotherapy that helps your immune system fight cancer, in people with advanced non-small cell lung cancer that has high PD-L1 protein (≥50%) and no treatable gene mutations. Researchers will also check a blood marker (c-FLIP) linked to certain immune cells to understand how well the treatment works.
This trial looks at adding atezolizumab to chemotherapy before surgery for resectable, non-squamous non-small cell lung cancer. It also tries to predict which patients will respond best using your tumor tissue.
This trial studies whether adding atezolizumab (an immune medicine) to standard platinum-based chemotherapy before surgery can improve outcomes for operable stage II–IIIB non-small cell lung cancer. The goal is to shrink the tumor and increase the chance the cancer can be removed with better results.
This trial tests a combination of two drugs (tislelizumab and anlotinib) for people with advanced lung cancer whose first immunotherapy treatment stopped working. The goal is to see if this new combination can help when the first treatment stopped being effective.
This study tests a combination of the immunotherapy drug atezolizumab with standard chemotherapy given before surgery for people with stage II to IIIB non-small cell lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improve outcomes.
Hear when a new NSCLC Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.